Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | CTSE | P14091 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324919 | 0.80 | USP2 (0.40) | USP2SMN1; SMN2DDB1CRBNGPR119 | |
| SCHEMBL17324920 | 0.80 | USP2 (0.40) | USP2SMN1; SMN2RECQLKDM4EMAPT | |
| SCHEMBL4542086 | 0.80 | USP2 (0.40) | USP2SMN1; SMN2TP53HRH3RECQL | |
| SCHEMBL19518174 | 0.79 | OPRM1 (0.49) | USP2SMN1; SMN2TP53HRH3RECQL | |
| SCHEMBL20555716 | 0.79 | OPRM1 (0.49) | USP2SMN1; SMN2TP53HRH3RECQL | |
| SCHEMBL17324903 | 0.79 | OPRM1 (0.49) | USP2SMN1; SMN2TP53HRH3RECQL | |
| SCHEMBL20555671 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2DDB1CRBNGPR119 | |
| SCHEMBL20475505 | 0.77 | HRH3 (0.50) | USP2SMN1; SMN2TP53HRH3RECQL | |
| SCHEMBL23481174 | 0.77 | HRH3 (0.43) | USP2SMN1; SMN2TP53HRH3RECQL | |
| SCHEMBL20621868 | 0.76 | USP2 (0.36) | USP2SMN1; SMN2KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149006-B1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| EP-3149006-B1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-20190177337-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-06-13 | — | — | US | disclosed |
| US-20190177337-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-06-13 | — | — | US | disclosed |
| US-10246465-B2 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-04-02 | — | — | US | disclosed |
| US-10246465-B2 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-04-02 | — | — | US | disclosed |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-02 | — | — | US | disclosed |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-02 | — | — | US | disclosed |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246465-B2 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | USP2 2147/4885SMN1; SMN2 708/4885TP53 4857/4885 |
| US-20190177337-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | USP2 2147/4885SMN1; SMN2 708/4885TP53 4857/4885 |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, SIGMAR1, OPRM1 | USP2 1847/4885SMN1; SMN2 775/4885TP53 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.